Absci Inc. has joined forces with Oracle Corporation's Oracle Cloud Infrastructure (OCI) and AMD Inc. to enhance generative AI-driven drug discovery efforts. The collaboration involves Absci's AI Drug Creation Platform, which utilizes OCI's AI infrastructure and AMD's newest hardware, leading to streamlined infrastructure and faster biologics design cycles. The partnership has allowed Absci to expedite development processes. The full article can be found on Benzinga.com.